作者
Zohreh Amoozgar, Jonas Kloepper, Jun Ren, Rong En Tay, Samuel W Kazer, Evgeny Kiner, Shanmugarajan Krishnan, Jessica M Posada, Mitrajit Ghosh, Emilie Mamessier, Christina Wong, Gino B Ferraro, Ana Batista, Nancy Wang, Mark Badeaux, Sylvie Roberge, Lei Xu, Peigen Huang, Alex K Shalek, Dai Fukumura, Hye-Jung Kim, Rakesh K Jain
发表日期
2022/1/1
期刊
Cancer Immunology Research
卷号
10
期号
1_Supplement
页码范围
P057-P057
出版商
The American Association for Cancer Research
简介
Glioblastoma (GBM) shows high level of resistance to currently available treatments including the standard of care and immunotherapy, representing the most fatal cancer type. Our study revealed that immune suppression by regulatory T cells (Treg) secondary to therapy with immune checkpoint blocker (anti-PD1) confers this resistance. In the GBM tumor microenvironment, Treg cells with increased suppressive phenotype were found of which frequency and anergic phenotype increase after ICB therapy, potentially contributing to the resistance. Targeting Treg has a dual-barreled effect on enhancing anti-tumor immunity: GBM is highly infiltrated with Treg while CD8 T cells are excluded. In view of Treg's intrinsic reactivity to self-antigens, mobilizing converted Treg as effector T cells can be an effective strategy to a tumor type that expresses a low level of neoantigens including GBM. Our study revealed that GITR …
学术搜索中的文章
Z Amoozgar, J Kloepper, J Ren, RE Tay, SW Kazer… - Cancer Immunology Research, 2022